29 December 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided ablation products Imricor is pleased to announce that to support the Company’s future growth strategy, Mr Gregg Stenzel has been appointed to the role of Chief Operating Officer, effective 1 January 2021. In this newly established role, Mr Stenzel will lead the execution of Imricor’s strategic plan across most functional areas of the business, providing greater capacity for CEO, Steve Wedan, to drive the establishment of new clinical sites as the business accelerates the commercial roll-out of its products across Europe in 2021.

10 December 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce they have entered into a Supply and Sales Agreement with Osypka AG Medizintechnik (Osypka), a German producer of radiofrequency ablation generators.

24 November 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce the University Hospital in Münster (UKM), Germany has signed a purchase agreement with Imricor, marking the ninth site the Company has contracted this year.

Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR guided cardiac ablation products, is pleased to announce the Schleswig-Holstein University Medical Centre (Universitätsklinikum Schleswig-Holstein, or UKSH), in Lübeck Germany, has signed a purchase agreement with Imricor. The Company is working with the Lübeck University Heart Centre, which is under the umbrella of UKSH, to schedule installation, training, and first procedures.

26 October 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in iCMR guided cardiac ablation products, is pleased to announce the Jaques Cartier Private Hospital’s Institut Cardiovasculaire Paris Sud (ICPS) has signed a purchase agreement with Imricor. The Company is working with the site to schedule installation, training, and first procedures.

28 September 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided ablation products, is pleased to announce the Rhön Clinic Bad Neustadt Campus in Bad Neustadt an der Saale, Germany has signed a purchase agreement with Imricor. The Company is working with the site to schedule installation, training, and first procedures.

27 September 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided ablation products, is pleased to announce it was awarded a contract from the US National Insitutues of Health (NIH) to develop an MRI comptabile myocardial biopsy system. Under the agreement, Imricor will receive US$399,539 over the next 12 months to develop a prototype system of devices that biopsy the inner walls of the heart, while using MR imaging to guide the procedure.

Imricor Medical Systems Inc (ASX:IMR) chair and CEO Steve Wedan speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.

12 August 2020 – Minneapolis, United States – Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in MRI-guided cardiac ablation products, is pleased to announce a sales collaboration with Optoacoustics Ltd, the world leader in innovative, high performance optical communication solutions for magnetic resonance (MR) applications.